Literature DB >> 30346346

Anatomical Look Into OnabotulinumtoxinA Injection for Chronic Migraine Headache.

Yuewei Wu-Fienberg, Hossein Ansari1, Shawn Zardouz1, Samer Narouze2, Taryn Blaha3, Marco Swanson4, Ali Totonchi5.   

Abstract

BACKGROUND AND OBJECTIVES: While existing studies about onabotulinumtoxinA for chronic migraines have focused on injection location and appropriate dosing, little consideration has been given to patient body habitus and its potential impact on efficacy. We hypothesized that with increasing patient body mass index (BMI) there would be more subcutaneous fat separating targeted muscle groups from the skin surface, such that standard 0.5-inch needles used in existing protocols may not allow intramuscular injection. This may have implications for treatment planning.
METHODS: Anatomically normal computed tomography scans of the head, neck, and face were randomly selected. Subjects were stratified into 4 groups based on BMI, with 30 patients in each group. Four standardized locations were chosen to obtain measurements from the skin surface to the underlying muscle fascia, including (1) frontalis, (2) temporalis, (3) semispinalis capitis, and (4) trapezius.
RESULTS: Median depth for the temporalis was 12.65 mm (Q1 = 9.32 mm, Q3 = 15.08 mm) for the BMI greater than 35 kg/m group. Median depth for the semispinalis capitis was 13.77 mm (Q1 = 10.3 mm, Q3 = 15.7 mm) for the BMI 30 to 35 kg/m group, and 14.75 mm (Q1 = 11.00, Q3 = 17.00 mm) for the BMI greater than 35 kg/m group. Median depth for the trapezius was 13.95 mm (Q1 = 10.18 mm, Q3 = 19.00 mm) for the BMI greater than 35 kg/m group. These medians exceeded the length of the standard 0.5-inch (12.-mm) needle used in existing protocols.
CONCLUSIONS: Our study demonstrates that with increasing BMI there is a greater distance between the skin surface and the muscle fascia of muscles that are targeted for injection in standard chronic migraine botulinum toxin injection protocols. Because of this, patient body habitus may be an important factor in injection technique.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30346346     DOI: 10.1097/AAP.0000000000000818

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  3 in total

1.  Botulinum toxin injection in the management of chronic migraine: the Saudi experience with a proposal for a new protocol.

Authors:  Hussein Algahtani; Bader Shirah; Ghassan Sukkar; Hatim Bukhari; Ibraheem Meftah; Asim Alhazmi; Abid Alshareef; Abdulmohsin Algethami; Ammar Alshanqiti; Mahmoud Andeejani
Journal:  Acta Neurol Belg       Date:  2020-10-14       Impact factor: 2.396

Review 2.  Perioperative management of antithrombotic therapy: a case-based narrative review.

Authors:  Andrew Tiger Chen; Matthew Patel; James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2021-10-15       Impact factor: 3.397

3.  Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine.

Authors:  Emmanouil V Dermitzakis; Michail Vikelis; George S Vlachos; Andreas A Argyriou
Journal:  Toxins (Basel)       Date:  2022-06-24       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.